Ozone Therapy in Refractory Ischemic Heart Disease.
Status:
Suspended
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The main objective of this clinical trial is to evaluate the effectiveness and
cost-effectiveness of adding ozone therapy to standard management of patients with advanced
ischemic heart disease refractory to medical and surgical treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bernardino Clavo, MD, PhD
Collaborators:
Colegio Oficial de Médicos de Las Palmas Fundación Canaria de Investigación Sanitaria Fundación MAPFRE Guanarteme Red de Investigación en Servicios de Salud en Enfermedades Crónicas Servicio Canario de Salud